Author:
Dorabawila Vajeera,Hoefer Dina,Bauer Ursula E.,Bassett Mary T.,Lutterloh Emily,Rosenberg Eli S.
Abstract
AbstractImportanceThere is limited evidence on the effectiveness of the BNT162b2 vaccine for children, particularly those 5-11 years and after the Omicron variant’s emergence.ObjectiveTo estimate BNT162b2 vaccine effectiveness against COVID cases and hospitalizations among children 5-11 years and 12-17 years during December, 2021 and January, 2022.DesignAnalyses of cohorts constructed from linked statewide immunization, laboratory testing, and hospitalization databases.Setting/ParticipantsNew York State children 5-17 years.Main outcomes/measuresNew laboratory-confirmed COVID-19 cases and hospitalizations. Comparisons were made using the incidence rate ratio (IRR), comparing outcomes by vaccination status, and estimated vaccine effectiveness (VE: 1-[1/IRR]).ResultsFrom December 13, 2021 to January 30, 2022, among 852,384 fully-vaccinated children 12-17 years and 365,502 children 5-11 years, VE against cases declined from 66% (95% CI: 64%, 67%) to 51% (95% CI: 48%, 54%) for those 12-17 years and from 68% (95% CI: 63%, 72%) to 12% (95% CI: 6%, 16%) for those 5-11 years. During the January 24-30 week, VE for children 11 years was 11% (95%CI -3%, 23%) and for those age 12 was 67% (95% CI: 62%, 71%). VE against hospitalization declined changed from 85% (95% CI: 63%, 95%) to 73% (95% CI: 53%, 87%) for children 12-17 years, and from 100% (95% CI: -189%, 100%) to 48% (95% CI: -12%, 75%) for those 5-11 years. Among children newly fully-vaccinated December 13, 2021 to January 2, 2022, VE against cases within two weeks of full vaccination for children 12-17 years was 76% (95% CI: 71%, 81%) and by 28-34 days it was 56% (95% CI: 43%, 63%). For children 5-11, VE against cases declined from 65% (95% CI: 62%, 68%) to 12% (95% CI: 8%, 16%) by 28-34 days.Conclusions and RelevanceIn the Omicron era, the effectiveness against cases of BNT162b2 declined rapidly for children, particularly those 5-11 years. However, vaccination of children 5-11 years was protective against severe disease and is recommended. These results highlight the potential need to study alternative vaccine dosing for children and the continued importance layered protections, including mask wearing, to prevent infection and transmission.
Publisher
Cold Spring Harbor Laboratory
Reference13 articles.
1. Effectiveness of BNT162b2 Vaccine against Delta Variant in Adolescents
2. Marks KJ , Whitaker M , Anglin O , et al. Hospitalizations of Children and Adolescents with Laboratory-Confirmed COVID-19 — COVID-NET, 14 States, July 2021–January 2022. MMWR Morb Mortal Wkly Rep. ePub: 15 February 2022. DOI: http://dx.doi.org/10.15585/mmwr.mm7107e4externalicon
3. Evaluation of mRNA-1273 SARS-CoV-2 vaccine in adolescents;N Engl J Med,2021
4. Safety, Immunogenicity, and Efficacy of the BNT162b2 Covid-19 Vaccine in Adolescents
5. Effectiveness of BNT162b2 Vaccine against Critical Covid-19 in Adolescents
Cited by
30 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献